The Sentinel


Tuesday, April 18, 2023



Hello JITC Readers,

It is my pleasure to welcome you to the latest edition of the JITC Digest. While I am honored to step into the role of Interim Editor-in-Chief, I must first send my sincerest thanks and appreciation to Founding Editor-in-Chief Pedro J. Romero for his guidance and dedication during his decade plus leading the journal. I encourage you all to view the special feature below, a thank you to Dr. Romero on behalf of JITC‘s Editorial Board and staff.

As JITC now opens a new chapter and enters its second decade, I am pleased to welcome Sjoerd van der Burg as Interim Deputy Editor-in-Chief. I look forward to working closely with him as we carry on the high quality and stellar reputation of the journal into a bright future. 

Change may be in the air at JITC, but unchanged is the commitment to continue publishing the best the immunotherapy field has to offer. Be sure to check out some of the top recent publications featured here in the Editor’s Picks. From identifying a population of CD163-expressing M2-like macrophages as key suppressors of T cell immunity with Marit J. van Elsas et al to a phase I, first-in-human trial that provides proof of principle that vaccination combined with checkpoint blockade may elicit antitumor T cell responses against prostate cancer by Karen A. Autio et al, there is something for everyone.

Finally, I would also like to thank the many of you who stopped by the SITC booth for the Meet the Editor activity during AACR 2023. It is always wonderful to see so many colleagues and discuss the latest science. If you couldn’t make it, join me at ASCO 2023 on Sunday, June 4th. I will be available for a Meet the Editor activity at 11am CT at the SITC booth (#2016). I hope to see you there!


James L. Gulley, MD, PhD, FACP
Journal for ImmunoTherapy of Cancer Interim Editor-in-Chief